| Literature DB >> 15984021 |
Diana M Escolar1, Gunnar Buyse, Erik Henricson, Robert Leshner, Julaine Florence, Jill Mayhew, Carolina Tesi-Rocha, Ksenija Gorni, Livia Pasquali, Kantilal M Patel, Robert McCarter, Jennifer Huang, Thomas Mayhew, Tulio Bertorini, Jose Carlo, Anne M Connolly, Paula R Clemens, Nathalie Goemans, Susan T Iannaccone, Masanori Igarashi, Yoram Nevo, Alan Pestronk, S H Subramony, V V Vedanarayanan, Henry Wessel.
Abstract
We tested the efficacy and safety of glutamine (0.6 gm/kg/day) and creatine (5 gm/day) in 50 ambulant boys with Duchenne muscular dystrophy in a 6-month, double-blind, placebo-controlled clinical trial. Drug efficacy was tested by measuring muscle strength manually (34 muscle groups) and quantitatively (10 muscle groups). Timed functional tests, functional parameters, and pulmonary function tests were secondary outcome measures. Although there was no statistically significant effect of either therapy based on manual and quantitative measurements of muscle strength, a disease-modifying effect of creatine in older Duchenne muscular dystrophy and creatine and glutamine in younger Duchenne muscular dystrophy cannot be excluded. Creatine and glutamine were well tolerated.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15984021 DOI： 10.1002/ana.20523
Source DB: PubMed Journal: Ann Neurol ISSN： 0364-5134 Impact factor: 10.422